Compare Becton Dickinson and Co (BDX) vs Herbalife Nutrition Ltd (HLF) Price & Performance

BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.

The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.

Herbalife (HLF) trades at $13.10, down 0.38% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 77.78% gross margin and attractive valuation metrics including a P/E of 5.75 and P/S of 0.27. Recent Q1 2026 earnings beat expectations with EPS of $0.64 versus $0.607 expected, while the company completed a $1.45 billion debt refinancing in April 2026 to strengthen its balance sheet.

The outlook remains positive with analyst consensus favoring Buy ratings (57.69%) and improving debt-to-asset ratios from 82.84% in 2024 to 71.67% in 2025. Key risks include high leverage, competitive pressures in the nutrition space, and regional market volatility. The stock offers value appeal given low multiples and recent strategic initiatives to expand digital health offerings.